Brand vs Compounded GLP-1 (2026): $349 Wegovy vs $149 Compound, Legal Status + Safety
Verified April 2026: Brand-name Wegovy is $349/mo via NovoCare, Zepbound starts at $299/mo via LillyDirect. Compounded semaglutide is banned since Feb 2025; compounded tirzepatide remains legal at $149-299/mo under narrow medical-necessity rules. Full legal + safety comparison.
Summarize this article with
Verified April 2026: Brand-name Wegovy costs $349/month through NovoCare, Zepbound costs $299-449/month through LillyDirect, and compounded semaglutide has been federally banned since April 22, 2025. Compounded tirzepatide remains legal under narrow medical-necessity exemptions and starts at $99 first month ($280/month after) through Enhance MD for compounded tirzepatide or $49 first month ($212/month after) through Enhance MD for compounded semaglutide. The $1,000-vs-$150 arbitrage that defined the 2023-2024 compound market no longer exists, brand prices dropped 70% and compounding enforcement ended shortage-based access.
Quick answer by situation:
- •Want a low-cost legal option today: Enhance MD from $49 first month compounded semaglutide (narrow medical-necessity) or Enhance MD from $99 first month compounded tirzepatide, both FDA-registered pharmacies.
- •Want FDA-approved brand at the lowest price: NovoCare Wegovy $349/month or LillyDirect Zepbound $299/month for the starter 2.5mg vial.
- •Medicare beneficiary: Coverage launches July 2026 at $50/month copay, see the Medicare Part D GLP-1 guide.
- •Still on compounded semaglutide: It's been enforced against since April 2025. See the compounded crackdown guide for switch options.
This guide breaks down the four-part decision, legality, safety, cost, and weight loss outcomes, using FDA enforcement timelines, current provider pricing, and clinical trial data. Patients who want to avoid injections entirely have two FDA-approved oral options starting at $149/mo, see the oral GLP-1 pills guide. Verify any provider with our FDA Safety Checker or compare all 48 telehealth programs by cost and score.
Comparing your options?
See every verified GLP-1 program ranked side by side on cost, safety, and care quality.
Compare all 52GLP-1 providers →What Are Compounded GLP-1s?
Compounded GLP-1 medications are custom-mixed formulations prepared by compounding pharmacies using the base active ingredient (semaglutide or tirzepatide). They are NOT FDA-approved products and they are NOT generics. There are two types of compounding pharmacies:
- •503A pharmacies: Traditional state-licensed compounding pharmacies that fill patient-specific prescriptions
- •503B outsourcing facilities: Larger-scale facilities registered with the FDA that can produce compounded drugs without patient-specific prescriptions
Every Tuesday. One email. The cheapest verified GLP-1 programs of the week.
Price drops, FDA alerts, new programs ranked, and compounded shortages, delivered Tuesday morning. No filler. Unsubscribe anytime.
No affiliate spam. No retargeting pixels. Unsubscribe in one click.
Are Compounded GLP-1s Still Legal in 2026?
Under federal law, compounding pharmacies can only produce copies of commercially available drugs when those drugs are in shortage. Here's what happened:
- •February 21, 2025: FDA removes semaglutide from the drug shortage list
- •April 22, 2025: Enforcement deadline for 503A (state-licensed) pharmacies to stop compounding semaglutide
- •May 22, 2025: Enforcement deadline for 503B outsourcing facilities
- •September 2025: FDA issues 50+ warning letters to compounders for false/misleading marketing claims
- •February 2026: FDA announces seizure and injunction powers against non-compliant compounders
- •April 30, 2026: FDA proposes permanent exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list (Federal Register publication May 1, 2026). FDA found no demonstrated clinical need for outsourcing facilities to compound these drugs from bulk substances. Comment period extended to July 30, 2026 (from June 29 via FR 2026-12937, published June 26, 2026) before any final rule.
Tirzepatide (Mounjaro/Zepbound) compounding enforcement ended even earlier, March 2025. A Texas federal judge upheld the ban.
Editor's Top Pick
Yucca Health
$146/mo · 7.7/10 · Compounded
Online weight-loss program by Yucca Health, Inc. (Beverly Hills, CA). Two named board-certified doctors, Dr. Michael Wasef MD and Dr. Andrew Sakla DO, handle prescribing. 20,000+ patients, 4.6 stars across 1,065 verified Trustpilot reviews. Starts at $146/mo for compounded semaglutide (custom-made version, not the FDA-approved brand) on the 6-month plan. Buy-now-pay-later via Klarna, Affirm, or Afterpay spreads the upfront commitment.
Are Compounded GLP-1s Safe?
The FDA has documented significant safety issues with compounded GLP-1 products:
- •520+ adverse event reports for compounded semaglutide as of April 2025
- •480+ adverse event reports for compounded tirzepatide
- •Reports of patients self-administering 5-20x the intended dose due to vial confusion
- •Impurities found up to 24% in some tested compounded products
- •Fraudulent products with fake pharmacy labels identified by regulators
- •Multiple hospitalizations documented
Not sure which GLP-1 program is right for you?
Take the 60-second quiz, we'll match you against 52 verified providers on your goals, budget, and medication preference, then surface your top 3.
Take the 60-sec QuizBrand vs Compounded: Direct Comparison
| Factor | Brand-Name | Compounded |
|---|---|---|
| FDA approved | Yes | No |
| Manufacturing | Full cGMP compliance | Varies by pharmacy |
| Quality testing | Extensive batch testing | Limited |
| Active ingredient | Exact patented formulation | May use different salt forms |
| Delivery | Pre-filled auto-injector pens | Vials with manual syringes |
| Monthly cost | $900-1,350 (list) / $349 (self-pay programs) | $149-299 (where still available) |
| Insurance eligible | Yes, with prior auth | Generally not covered |
| Legal status (2026) | Fully legal | Restricted to narrow medical-necessity cases |
What This Means for You in 2026
The compounded GLP-1 market hasn't disappeared entirely, but it has shrunk significantly according to the FDA's compounding policy update. Some providers still offer compounded options under narrow medical-necessity exemptions (e.g., documented allergy to inactive ingredients in brand products). Compounding for cost savings alone is not a legally valid basis. Notably, Embody offers compounded tirzepatide in an oral gum format, an alternative for patients who cannot tolerate injections, starting at $149 for the first month.
The good news: brand-name prices have dropped substantially. Novo Nordisk now offers Wegovy/Ozempic at $349/month through self-pay programs, and Eli Lilly sells Zepbound vials for $299-449/month through LillyDirect. Medicare coverage at $50/month copay launches in July 2026. These changes narrow the price gap considerably.
If you were on compounded semaglutide specifically, the FDA ban has already taken effect. See our detailed compounded semaglutide crackdown guide for a full breakdown of your options, including compounded tirzepatide, which remains legal and starts at $149/month.
The Lawsuit Landscape
Both major GLP-1 manufacturers have been aggressively protecting their products:
- •Novo Nordisk filed 130+ lawsuits against compounders across 40 states
- •Novo Nordisk sued Hims & Hers in February 2026; they settled in March 2026 with a partnership deal for Hims to distribute branded Wegovy
- •Eli Lilly sued multiple telehealth companies and compounders
- •Strive Pharmacy filed an antitrust countersuit against both companies in January 2026
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. Information is current as of the publication date but may change.
Affiliate Disclosure: Some links in this article are affiliate links. We may earn a commission if you sign up through our links, at no extra cost to you.
Find your GLP-1 program, our Top Pick is Yucca Health
Our featured pick, drawn from our independent ranking of 52 verified providers, at $146/mo all-in.
Featured affiliate pick, we may earn a commission · scores set by our methodology, not payment
Compare every GLP-1 program in one place
See all 52 verified providers ranked side by side on price, medication, and our independent score, or jump straight to the cheapest verified prices.
Medicare & GLP-1
Medicare GLP-1 Coverage Guide
Saw Medicare mentioned in "Brand vs Compounded GLP-1 (2026): $349 Wegovy vs $149 Compound, Legal Status + Safety"? Here's exactly what's covered, who qualifies, and how the $50/mo Bridge copay works from July 1, 2026.
Read the Medicare Coverage Guide →Ozempic vs Wegovy (2026): Same Drug, $1,028 vs $1,349 List, Here's Which You Need
GuidesFirst Month on GLP-1 (2026): 2-5 lbs Lost Week 1-4, Nausea Peaks Week 4, Week-by-Week
ComparisonsMounjaro vs Ozempic (2026): The Honest Head-to-Head Your Doctor Won't Have Time For
Keep exploring
- →Provider Rankings
- →Cheapest Providers
- →Take the Match Quiz
- →Weight Loss Predictor
- →Full Cost Guide
- →Cost Calculator
What the doctors say
Verbatim, independently sourced statements from named physicians and medical bodies, real clinicians quoted with their sources, not a single paid reviewer. General clinical context, not an endorsement of any provider.
“So-called 'weight loss drugs' like semaglutide have proven benefits beyond reducing the number on the scales – they are now considered important medicines for preventing deadly heart attacks and strokes. Today's guidance will no doubt help save lives as cardiovascular disease is still one of the country's biggest killers.”
“While compounding can play an appropriate role when used to meet the specific needs of an individual patient, the large-scale production and marketing of compounded versions of these medicines raises serious safety risks when products have not undergone the rigorous scientific and regulatory review required for FDA-approved therapies.”
“It's not just filling out a form online and then having some random healthcare provider sign off on it. There are concerns with some of these online programs that there's not a proper evaluation, there's not a baseline, and there's not proper supervision.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.